Previous close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 30.00 |
Expiry date | 2024-06-21 |
Day's range | 0.4000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | 2.64k |
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BSTCompany to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
4D Molecular Therapeutics ( NASDAQ:FDMT ) First Quarter 2024 Results Key Financial Results Revenue: US$28.0k (down 91...